Geron mit Hammernews!! (Seite 76)
eröffnet am 18.03.03 18:26:10 von
neuester Beitrag 21.03.24 13:47:21 von
neuester Beitrag 21.03.24 13:47:21 von
Beiträge: 3.090
ID: 709.348
ID: 709.348
Aufrufe heute: 0
Gesamt: 213.087
Gesamt: 213.087
Aktive User: 0
ISIN: US3741631036 · WKN: 902213 · Symbol: GON
3,6780
EUR
0,00 %
0,0000 EUR
Letzter Kurs 02.05.24 Tradegate
Neuigkeiten
02.05.24 · Business Wire (engl.)  |
25.04.24 · Business Wire (engl.) |
18.04.24 · Business Wire (engl.) |
03.04.24 · Business Wire (engl.) |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,7850 | +42,80 | |
| 1,6600 | +32,80 | |
| 5,8700 | +26,24 | |
| 5,5500 | +26,14 | |
| 3,6500 | +21,26 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,5000 | -26,24 | |
| 0,6700 | -26,58 | |
| 6,4500 | -33,85 | |
| 2,1300 | -34,41 | |
| 3,1600 | -38,64 |
Beitrag zu dieser Diskussion schreiben
Feedback
es geht los!!!
U.S. Representative James Forbes submits new stem cell bill
http://www.govtrack.us/congress/bill.xpd?bill=h111-877
H.R. 877:
111st Congress
This is a bill in the U.S. Congress originating in the House of Representatives ("H.R."). A bill must be passed by both the House and Senate and then be signed by the President before it becomes law.
Bill numbers restart from 1 every two years. Each two-year cycle is called a session of Congress. This bill was created in the 111st Congress, in 2009-2010.
The titles of bills are written by the bill's sponsor and are a part of the legislation itself. GovTrack does not editorialize bill summaries.
2009-2010
To intensify stem cell research showing evidence of substantial clinical benefit to patients, and...
To intensify stem cell research showing evidence of substantial clinical benefit to patients, and for other purposes.
U.S. Representative James Forbes submits new stem cell bill
http://www.govtrack.us/congress/bill.xpd?bill=h111-877
H.R. 877:
111st Congress
This is a bill in the U.S. Congress originating in the House of Representatives ("H.R."). A bill must be passed by both the House and Senate and then be signed by the President before it becomes law.
Bill numbers restart from 1 every two years. Each two-year cycle is called a session of Congress. This bill was created in the 111st Congress, in 2009-2010.
The titles of bills are written by the bill's sponsor and are a part of the legislation itself. GovTrack does not editorialize bill summaries.
2009-2010
To intensify stem cell research showing evidence of substantial clinical benefit to patients, and...
To intensify stem cell research showing evidence of substantial clinical benefit to patients, and for other purposes.
in den nächsten Wochen wirds heiss hergehen... Schaut euch mal die Optionsumsätze an der ISE an...
hier ein Kommentar von Schaeffler Research:
http://www.schaeffersresearch.com/commentary/observations.as…
Analyzing Massive Call Volume on Geron Corporation, By the Numbers
Can this stem cell stock convince investors that its rally is for real?
by Elizabeth Harrow and Rocky White 2/5/2009 12:13 PM
As you may have noticed, we keep a close eye on unusual developments in the fast-paced and glamorous world of options trading. Thanks to this diligence, it has not escaped our notice that buy-to-open call volume has absolutely exploded on Geron Corporation ( GERN: View sentiment for GERNsentiment, chart, options) during the past couple of weeks. Yes, this surge in optimistic option activity is supported by a positive fundamental development -- but, with everyone piling onto the bullish bandwagon, how long can the stock extend its rally?
FDA decision sparks massive call volume
First things first -- let's explain why GERN is attracting so much enthusiasm from speculative investors. Back on Jan. 23, the stock spiked sharply higher after word hit the Street that the U.S. Food and Drug Administration (FDA) granted its approval for the world's first clinical trial of human embryonic stem cell therapy.
Previously, the agency had rejected Geron's request to conduct a trial of its GRNOPC1 drug. With this regulatory hurdle cleared, investors flocked to buy the stock's call options (apparently, tens of thousands of traders have absolutely no moral qualms about the often-controversial topic of embryonic stem cells).
Lest you think we're exaggerating, let's define what we mean when we refer to "massive" call volume. Year-to-date, about 47,500 calls have been bought to open on the International Securities Exchange (ISE), compared to about 3,700 puts. On Jan. 23 alone, there were about 17,000 calls bought to open and 750 puts bought to open.
Most of the recent call additions have been focused around the February options series, which expires in a couple of weeks. There are 12,189 call contracts in residence at the 7.50 strike, and 10,693 calls open at the 10 strike. The 7.50 call is also the most popular option in the March series, where there are 9,000 open contracts.
Thanks to the FDA-related boost, GERN has rocketed to a year-to-date gain of 62.7%. However, the shares' momentum stalled out near the 8 level, and they're now trading nearly flat with the closely watched 7.50 strike. With February expiration approaching the Friday after next, this region could exert some options-related resistance on the shares during the short term.
n fact, this unfavorable open interest configuration has us a little concerned about the short-term prospects for GERN. Is the equity's rally on its last legs?
Is there any room left on the bandwagon?
We decided to check out the rest of the stock's sentiment backdrop to see if any additional buyers are still lingering on the sidelines. GERN's Schaeffer's put/call open interest ratio (SOIR) has pulled back sharply of late, moving inversely to the equity's powerhouse rally. Now, the SOIR is docked at 0.23, with calls more than quadrupling puts among near-term options. This ratio ranks lower than 78% of other such readings taken during the past year, underscoring the recent upswing in option-player optimism.
While we would expect the SOIR to decline as the stock rises, it's troubling in the context of GERN's recent price action -- which has been primarily sideways. If this heavily bullish group grows discouraged, an unwinding of long positions could apply new selling pressure.
GERN short interestAs for short sellers, it seems that short interest on GERN has steadily declined since August 2008. Now, the number of shares sold short is near a 1-year low. However, it's all relative -- this apparently low number still accounts for a healthy 10.9% of the stock's available float, or 10.2 times its average daily volume. These bearish bets represent a potential source of buying pressure for GERN.
Additional attention from analysts could also serve as a positive catalyst, as Zacks reports just 1 "buy" and 1 "hold" rating. Any bullish initiations or upgrades could draw another wave of buyers to the stock.
The long and short of it
While we're encouraged by the respectable amount of short interest on GERN, we're still hung up on the 7.50 level... and, as contrarians, we can't help but be leery of the bandwagon mentality among option players. It seems that some investors have already priced in plenty of upside, which means the security has high expectations to meet.
Additionally, there's no denying that buying power has waned since the stock's initial pop higher. During the short term, traders should keep an eye on the 7.50 strike. If the shares fail to surmount this level during the next week or 2, it could prompt some frustrated bulls to hit the exits, and the equity may even be forced to fill in its bull gap.
On the other hand, a successful journey atop this region could convince the lingering skeptics of GERN's strength, resulting in additional gains. Overall, proceed with caution when it comes to this stem cell concern. The potential for further gains is there, but the stock will have to convince the remaining bears that its rally has legs to run higher.
As always, please contact us with any questions, comments, or suggestions for future columns. For more commentary on today's market-moving news, please visit our Schaeffer's Daily Market Blog section throughout the trading day.
hier ein Kommentar von Schaeffler Research:
http://www.schaeffersresearch.com/commentary/observations.as…
Analyzing Massive Call Volume on Geron Corporation, By the Numbers
Can this stem cell stock convince investors that its rally is for real?
by Elizabeth Harrow and Rocky White 2/5/2009 12:13 PM
As you may have noticed, we keep a close eye on unusual developments in the fast-paced and glamorous world of options trading. Thanks to this diligence, it has not escaped our notice that buy-to-open call volume has absolutely exploded on Geron Corporation ( GERN: View sentiment for GERNsentiment, chart, options) during the past couple of weeks. Yes, this surge in optimistic option activity is supported by a positive fundamental development -- but, with everyone piling onto the bullish bandwagon, how long can the stock extend its rally?
FDA decision sparks massive call volume
First things first -- let's explain why GERN is attracting so much enthusiasm from speculative investors. Back on Jan. 23, the stock spiked sharply higher after word hit the Street that the U.S. Food and Drug Administration (FDA) granted its approval for the world's first clinical trial of human embryonic stem cell therapy.
Previously, the agency had rejected Geron's request to conduct a trial of its GRNOPC1 drug. With this regulatory hurdle cleared, investors flocked to buy the stock's call options (apparently, tens of thousands of traders have absolutely no moral qualms about the often-controversial topic of embryonic stem cells).
Lest you think we're exaggerating, let's define what we mean when we refer to "massive" call volume. Year-to-date, about 47,500 calls have been bought to open on the International Securities Exchange (ISE), compared to about 3,700 puts. On Jan. 23 alone, there were about 17,000 calls bought to open and 750 puts bought to open.
Most of the recent call additions have been focused around the February options series, which expires in a couple of weeks. There are 12,189 call contracts in residence at the 7.50 strike, and 10,693 calls open at the 10 strike. The 7.50 call is also the most popular option in the March series, where there are 9,000 open contracts.
Thanks to the FDA-related boost, GERN has rocketed to a year-to-date gain of 62.7%. However, the shares' momentum stalled out near the 8 level, and they're now trading nearly flat with the closely watched 7.50 strike. With February expiration approaching the Friday after next, this region could exert some options-related resistance on the shares during the short term.
n fact, this unfavorable open interest configuration has us a little concerned about the short-term prospects for GERN. Is the equity's rally on its last legs?
Is there any room left on the bandwagon?
We decided to check out the rest of the stock's sentiment backdrop to see if any additional buyers are still lingering on the sidelines. GERN's Schaeffer's put/call open interest ratio (SOIR) has pulled back sharply of late, moving inversely to the equity's powerhouse rally. Now, the SOIR is docked at 0.23, with calls more than quadrupling puts among near-term options. This ratio ranks lower than 78% of other such readings taken during the past year, underscoring the recent upswing in option-player optimism.
While we would expect the SOIR to decline as the stock rises, it's troubling in the context of GERN's recent price action -- which has been primarily sideways. If this heavily bullish group grows discouraged, an unwinding of long positions could apply new selling pressure.
GERN short interestAs for short sellers, it seems that short interest on GERN has steadily declined since August 2008. Now, the number of shares sold short is near a 1-year low. However, it's all relative -- this apparently low number still accounts for a healthy 10.9% of the stock's available float, or 10.2 times its average daily volume. These bearish bets represent a potential source of buying pressure for GERN.
Additional attention from analysts could also serve as a positive catalyst, as Zacks reports just 1 "buy" and 1 "hold" rating. Any bullish initiations or upgrades could draw another wave of buyers to the stock.
The long and short of it
While we're encouraged by the respectable amount of short interest on GERN, we're still hung up on the 7.50 level... and, as contrarians, we can't help but be leery of the bandwagon mentality among option players. It seems that some investors have already priced in plenty of upside, which means the security has high expectations to meet.
Additionally, there's no denying that buying power has waned since the stock's initial pop higher. During the short term, traders should keep an eye on the 7.50 strike. If the shares fail to surmount this level during the next week or 2, it could prompt some frustrated bulls to hit the exits, and the equity may even be forced to fill in its bull gap.
On the other hand, a successful journey atop this region could convince the lingering skeptics of GERN's strength, resulting in additional gains. Overall, proceed with caution when it comes to this stem cell concern. The potential for further gains is there, but the stock will have to convince the remaining bears that its rally has legs to run higher.
As always, please contact us with any questions, comments, or suggestions for future columns. For more commentary on today's market-moving news, please visit our Schaeffer's Daily Market Blog section throughout the trading day.
Antwort auf Beitrag Nr.: 36.503.845 von revolt am 03.02.09 18:13:08Die ganze Börse ist zur Zeit ein Zock.Wird die Coba zB.komplett verstaatlicht und die Aktionäre enteignet steht sie bei 0,0.
Sie kann sich aber auch vervielfachen.So ist es auch bei Geron.
Ich hab mich für Geron entschieden.Die Banken haben fertig.
Sie kann sich aber auch vervielfachen.So ist es auch bei Geron.
Ich hab mich für Geron entschieden.Die Banken haben fertig.
Antwort auf Beitrag Nr.: 36.501.689 von optschraub am 03.02.09 13:54:58Ja, das ist klar... Wird wohl nen Zock bleiben, weil wenn der stirbt wars das mit der Aktie
Antwort auf Beitrag Nr.: 36.498.529 von revolt am 02.02.09 22:45:14Hallo!
Also wenn der erste Querschnittgelähmte wieder läuft ist der Einstieg zu spät warscheinlich...besser wenn es an den Zehen anfängt zu kribbeln...
Also wenn der erste Querschnittgelähmte wieder läuft ist der Einstieg zu spät warscheinlich...besser wenn es an den Zehen anfängt zu kribbeln...
Trading Spotlight
meint ihr es lohnt sich noch drauf zuspringen? Wäre nur nen kleiner zock.. aber der sollte ja auch was bringen
lg
lg
January 29, 2009, 2:15 PM
Obama's Science Grade, A New Ice Age, And A Hint Of Google
Posted by Daniel Sieberg
Scientists across the country have heralded the Obama administration's approach to research and development. Already it’s a stark contrast to the Bush years. But what exactly will be done for areas like stem cells, global warming, and space exploration?
These are some of the questions that we try to answer in an upcoming story for the CBS Evening News with Katie Couric. It may be airing tomorrow (Friday) night. We spoke to a number of prominent people from all those fields about their expectations and hopes. We also talked to one woman who may be directly affected by any policy decisions; she puts a human face on all the scientific data and studies.
Also, before cozying up for commercials and football this weekend, I hope you'll tune in to CBS Sunday Morning. It's the 30th anniversary edition of the beloved program (OK, I'm a little biased), and I'm contributed a story about ice. Yes, ice. As in cubes. But not just any old frozen water. For those who enjoy imbibing a good cocktail it can be the unsung hero by adding a touch of class or esthetic. But at too many bars or (Super Bowl) parties the ice ends up melting in such a hurry that it ruins the work of your favorite mixologist. It's also a story about people who carve ice, eat ice (true), and generally believe that ice is now hot. You'll have to watch to find out more -- including the secrets to a bar in Las Vegas that's all made of ice, even the glasses.
Finally, a little teaser -- on Monday night's CBS Evening News with Katie Couric we're planning to have a story about a new Google tool. Can't say more than that right now but I hope you'll join us.
In the meantime, stay connected.
http://www.cbsnews.com/blogs/2009/01/29/eveningnews/techtalk…
Obama's Science Grade, A New Ice Age, And A Hint Of Google
Posted by Daniel Sieberg
Scientists across the country have heralded the Obama administration's approach to research and development. Already it’s a stark contrast to the Bush years. But what exactly will be done for areas like stem cells, global warming, and space exploration?
These are some of the questions that we try to answer in an upcoming story for the CBS Evening News with Katie Couric. It may be airing tomorrow (Friday) night. We spoke to a number of prominent people from all those fields about their expectations and hopes. We also talked to one woman who may be directly affected by any policy decisions; she puts a human face on all the scientific data and studies.
Also, before cozying up for commercials and football this weekend, I hope you'll tune in to CBS Sunday Morning. It's the 30th anniversary edition of the beloved program (OK, I'm a little biased), and I'm contributed a story about ice. Yes, ice. As in cubes. But not just any old frozen water. For those who enjoy imbibing a good cocktail it can be the unsung hero by adding a touch of class or esthetic. But at too many bars or (Super Bowl) parties the ice ends up melting in such a hurry that it ruins the work of your favorite mixologist. It's also a story about people who carve ice, eat ice (true), and generally believe that ice is now hot. You'll have to watch to find out more -- including the secrets to a bar in Las Vegas that's all made of ice, even the glasses.
Finally, a little teaser -- on Monday night's CBS Evening News with Katie Couric we're planning to have a story about a new Google tool. Can't say more than that right now but I hope you'll join us.
In the meantime, stay connected.
http://www.cbsnews.com/blogs/2009/01/29/eveningnews/techtalk…
Here we go!
http://www.whas11.com/medical/stories/012409whascwTopStemCel…
President Obama to reverse stem cell research funding restrictions
04:31 PM EST on Tuesday, January 27, 2009
Early next week, President Obama is planning on reversing the restrictions imposed by President Bush, which will allow federal funding of embryonic stem cell research.
This is major, new health news from the office of the president, for supporters of those asking for permission to use embryonic stem cells in clinical trials to treat human paralysis.
The first trial is already planned and will be small; only eight-to-ten people in a bio tech company in California. The patients will be paraplegics who can use their arms, but cannot walk. They will receive one injection within two weeks of their injury.
Dr. David Scadden, Harvard Stem Cell Institute, said “If we could have any evidence of activity, if they could now feel cold, or warm or touch, that would be a sign of success.”
This first test will show only if the cells are safe in humans. Animal research has been very successful. Scientists have helped paralyzed rats walk again by repairing damaged nerve endings in their spines.
Web story published by Chris Wright
http://www.whas11.com/medical/stories/012409whascwTopStemCel…
President Obama to reverse stem cell research funding restrictions
04:31 PM EST on Tuesday, January 27, 2009
Early next week, President Obama is planning on reversing the restrictions imposed by President Bush, which will allow federal funding of embryonic stem cell research.
This is major, new health news from the office of the president, for supporters of those asking for permission to use embryonic stem cells in clinical trials to treat human paralysis.
The first trial is already planned and will be small; only eight-to-ten people in a bio tech company in California. The patients will be paraplegics who can use their arms, but cannot walk. They will receive one injection within two weeks of their injury.
Dr. David Scadden, Harvard Stem Cell Institute, said “If we could have any evidence of activity, if they could now feel cold, or warm or touch, that would be a sign of success.”
This first test will show only if the cells are safe in humans. Animal research has been very successful. Scientists have helped paralyzed rats walk again by repairing damaged nerve endings in their spines.
Web story published by Chris Wright
Durchsuchen
